Steven Cohen’s Orchestra BioMed OBIO Stock Holding History

Steven Cohen’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-87,888	Closed	-$374K	–	4428
2026 Q1	$374K	Sell	87,888 -74,058	-46%	-$315K	﹤0.01%	3268
2025 Q4	$672K	Buy	+161,946	New	+$653K	﹤0.01%	3083

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Steven Cohen's OBIO Position: Q2 2026 in Review

Steven Cohen sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 87,888 shares — an estimated $374K sold.

Steven Cohen first reported a position in OBIO in Q4 2025 and held it in 2 quarters. The position peaked at $672K in Q4 2025. 76 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Steven Cohen reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 87,888 Orchestra BioMed shares in Q2 2026, an estimated $374K.
Steven Cohen first reported a position in Orchestra BioMed in Q4 2025 and held it in 2 quarters.
Steven Cohen's Orchestra BioMed position peaked at $672K in Q4 2025.
76 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.